News
February 19, 2014

NPR Covers Cancer Commons

Uncategorized

CommonHealth, a blog affiliated with Boston’s NPR news station WBUR, recently posted an interview with Cancer Commons founder Marty Tenenbaum. Reporter Rachel Zimmerman caught up with Marty after a talk he gave at MIT in Cambridge. Marty told her his personal story, explained why Cancer Commons is collecting stories from other patients, and placed Cancer Commons’ efforts in the context of rapidly evolving understanding of the science behind cancer.

A quote from Marty: ” ‘We’re patient focused and science based; Our mission is to aggregate and analyze data, to provide patients with the best information — up-to-the-moment, personalized, and actionable to help them make informed decisions…like a Lonely Planet guide to cancer.’ ”

Read the full post here

January 21, 2014

Nature Reviews Clinical Oncology Publishes Paper by Marty Tenenbaum

Uncategorized

The journal, Nature Reviews Clinical Oncology, published a paper written by Cancer Commons founder Marty Tenenbaum and co-author Jeff Shrager. The piece discusses the concept of Rapid Learning Precision Oncology. In this approach, every patient receives the best available treatment for them, based on the specifics of their diagnosis. Then the outcomes (e.g., tumor shrinkage, side effects, quality of life, etc.) are used to support and refine the treatment model on which patients’ treatment decisions are based. Tenenbaum and Shrager review the Rapid Learning Precision Oncology approach and the many challenges to its implementation.

Read the article: Rapid learning for precision oncology. Nature Reviews Clinical Oncology. Jan 21, 2014. doi: 10.1038/nrclinonc.2013.244

Click here for a pdf copy.

October 26, 2012

Cancer Commons To Participate on the Stand Up To Cancer West Coast Dream Team for Prostate Cancer

Uncategorized

A multi-center “dream team’’ of scientists, led by UCSF, is embarking on a groundbreaking $10M initiative in personalized medicine, to overcome therapeutic resistance in patients with advanced prostate cancer.

Cancer Commons is supporting the Team through collaboration with Ted Goldstein and Josh Stuart of UCSC on the development of Medbook, a “Facebook for Cancer,” which will connect the team’s scientists and clinicians in a “rapid learning community”.  Participants will be able to collaboratively analyze and discuss the data from refractory prostate cancer patients at all participating centers, to identify the molecular drivers of this disease and optimal interventions.  This knowledge will be continually tested and refined based on the latest laboratory and clinical findings.  Our vision is for every patient to be treated using the best and most up-to-date knowledge and to update that knowledge based on each patient’s response. Clinically actionable results will be rapidly disseminated through Medbook to affected patients and their physicians.

Learn more about this exciting initiative at UCSF.

July 2, 2012

Tegal acquisition of CollabRx will bring interpretive content and data analytics to genomics-based medicine

Announcements, In the News

Petaluma, Calif., July 2, 2012 — Tegal Corporation (NASDAQ: TGAL) today announced that it has signed a definitive agreement to acquire CollabRx, Inc., a privately held technology company in the rapidly growing market of interpretive content and data analytics for genomics-based medicine.

CollabRx offers cloud-based expert systems that provide clinically relevant interpretive knowledge to institutions, physicians, researchers and patients for genomics-based medicine in cancer and other diseases to inform health care decision making. With access to approximately 50 clinical and scientific advisors at leading academic institutions and a suite of tools and processes that combine artificial intelligence-based analytics with proprietary interpretive content, the company is well positioned to participate in the $300 billion value-added “big data” opportunity in the US health care market (as reported by McKinsey Global Institute), over half of which specifically targets areas in cancer and cancer genomics.1

The Chief Executive Officers of the two constituent companies, Thomas Mika of Tegal and James Karis of CollabRx, plan to serve as co-CEOs of the combined, publicly traded company, with headquarters in San Francisco, CA. Tegal entered into an employment agreement with Mr. Karis that will become effective at the closing, and Mr. Karis will also be appointed to Tegal’s Board of Directors. Tegal will continue to operate under its current name and ticker symbol for the time being, but plans to seek stockholder approval at its upcoming annual meeting in September 2012 for an amendment to its Certificate of Incorporation, changing its corporate name to CollabRx, Inc.

Originally founded in 2008 by Silicon Valley Internet pioneer Jay (Marty) Tenenbaum, CollabRx has developed clinical advisory networks, expert systems, proprietary tools and processes, and a pipeline of commercial data products and applications (“apps”) for cancer. CollabRx Therapy Finders™, its first commercial product, provides sophisticated, credible, personalized, and actionable information to physicians and patients for rapidly determining which medical tests, therapies, and clinical trials may be considered in cancer treatment planning with a specific emphasis on the tumor genetic profile.

CollabRx Therapy Finders™ are web-based apps that serve as one type of user interface to access proprietary CollabRx content. CollabRx content is dynamically updated and organized in a knowledgebase that includes information on molecular diagnostics, medical tests, clinical trials, drugs, biologics and other information relevant for cancer treatment planning. Capturing how highly respected practicing physicians use this information in the clinical setting further refines the knowledgebase.

Upon the acquisition’s closing, Tegal will issue an aggregate of 236,433 shares of common stock, representing 14% of Tegal’s total shares outstanding prior to the closing, to former CollabRx stockholders in exchange for 100% of the capital stock of CollabRx, Inc. Tegal and certain former CollabRx stockholders will enter into a Stockholders Agreement providing for, among other things, registration rights, transfer restrictions and voting and standstill agreements. Tegal also will assume $500,000 of existing CollabRx indebtedness through the issuance of 5-year promissory notes in substitution for outstanding notes previously issued by CollabRx. In addition, Tegal will grant a total of 368,417 RSUs and options as “inducement grants” to newly hired management and employees, all subject to four-year vesting and other restrictions.

“Medicine is entering a new era of low cost genome sequencing and the proliferation of personalized treatments based on specific genetic mutations,” said James Karis, CEO of CollabRx. “With the technology platform and expert system leadership position that CollabRx has developed over the past few years, we believe that the new company is in a position to lead the market for accurate, credible and current genomic information in the cancer space. We are excited to be joining the Tegal management team in a well-resourced, publicly-traded entity.”

“This acquisition marks both the successful conclusion of a transition process and the beginning of a new chapter for Tegal Corporation,” said Thomas Mika, Tegal’s Chairman, President and CEO. “We are excited to help drive the rapid growth of this market while we meet a critical and consequential human need. This is a mission Tegal’s board has embraced wholeheartedly. I am very pleased to be working with James Karis as Co-CEO and fellow director, and look forward, along with the entire team at CollabRx and Tegal, to building a dynamic company in a new era of genomic medicine.”

1 ”Big data: The next frontier for innovation, competition and productivity”, McKinsey Global Institute, May 2011

About Tegal

Since its founding in 1972, Tegal Corporation has been dedicated to the development and application of emerging technologies. For 40 years, Tegal’s process and equipment know-how has been incorporated in devices fabricated by some of the world’s leading semiconductor and MEMS companies, including Tegal’s one-time parent, Motorola. Now entering its fifth decade, Tegal has committed its future to emerging technologies in medical devices and health care. Please visit us on the web at www.tegal.com.

About CollabRx

CollabRx is a recognized leader in “cloud-based” expert systems to inform health care decision-making. CollabRx uses information technology to aggregate and contextualize the world’s knowledge on genomics-based medicine with specific insights from the nation’s top cancer experts starting with the area of greatest need: advanced cancers in patients who have effectively exhausted the standard of care.

Safe Harbor Statement

This press release contains forward-looking statements that may include statements regarding the intent, belief or current expectations of Tegal, CollabRx and their respective management. Forward looking statements include statements about the benefits and advantages of the acquisition for Tegal and CollabRx. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of important factors, including but not limited to the risk that the acquisition will not close as the transaction is subject to certain closing conditions. In addition, if and when the transaction is closed, there will be risks and uncertainties related to Tegal’s ability to integrate CollabRx successfully, the risk that the anticipated benefits from the acquisition may not be fully realized or may take longer to realize than expected; and competition and its effect on the combined company’s performance. Additional factors that may affect future results are contained in the SEC filings for Tegal, including but not limited to Tegal’s Annual Report on Form 10-K for the year ended March 31, 2012. Tegal and CollabRx each disclaim any obligation to update and revise statements contained in this release based on new information or otherwise.

Contact:

Tegal Corporation
Thomas Mika, President & CEO
(707) 763-5600 x5630
tmika@tegal.com

 

February 21, 2012

Cancer Commons Researchers Publish Molecular Disease Model for Lung Cancer

In the News

PALO ALTO, Calif.–(BUSINESS WIRE)–Cancer Commons, an open‐science initiative to personalize cancer treatments and accelerate research, announces the publication of a molecular disease model (MDM) for lung cancer. The paper, by Lisandra West, Ravi Salgia, and others will appear in the February 21st issue of PLoS ONE (http://www.plosone.org).

The lung cancer MDM classifies the disease into subtypes based on a tumor’s histology and its molecular profile. Each subtype is then linked to published clinical treatment guidelines and other proposed therapy options, including investigational agents available through clinical tests. This information can help physicians understand therapy options for individual patients based on their tumor’s molecular subtype. Going forward, the resulting clinical responses can be used to refine the model. The MDM is a living review article, maintained by experts and continually updated based on input from the entire cancer community. The most recent version is available online at:

Lung Cancer Molecular Disease Model

Cancer Commons has assembled an elite group of volunteer clinical and translational scientists to create MDMs for lung and other common cancers under the leadership of George Lundberg, MD, Cancer Commons Senior Advisor. The editorial process ensures a lack of bias and conflict of interest in the construction of these models from a scientific and medical perspective. Cancer Commons relies on organizations such as Pfizer Inc. for the financial support required to develop the models and make them freely available, as an educational and scientific resource.

“This molecular disease model for such a common serious cancer provides the opportunity for patients (even late stage) and their physicians to work together to access promising new therapies,” said Dr. George Lundberg, MD, former editor‐in‐chief of JAMA, and a member of the Cancer Commons Advisory Board.

“The Lung Cancer model supplies doctors and their patients with a clear, high‐level guide to how tumor genetics can be leveraged to inform treatment decisions. The model helps physicians evaluate options in designing an optimal treatment plan for their patients,” said Ravi Salgia, M.D., Chief Editor of the Lung Cancer MDM, and a Cancer Commons Advisory Board Member.

“CollabRx is very excited to have been a collaborator on this important open science initiative. Using technology to make the best science readily accessible to patients and their physicians in the rapidly emerging field of personalized medicine is the very reason we were founded,” said James Karis, CEO of CollabRx, a cancer informatics company that collaborated on the development of the MDM.

“Pfizer is committed to improving the standard of care for patients with lung cancer, and central to that commitment is our belief that each patient’s tumor is genetically unique,” said Dr. Martine George, Vice President of Global Medical Affairs, Pfizer Oncology. “In providing financial support for this important open-science initiative, we are aiming to help physicians and patients understand the therapeutic options that best fit the patient’s molecular profile, with the goal of delivering more effective, personalized care.”

About Cancer Commons 

Cancer Commons is a non‐profit open science initiative dedicated to improving outcomes for today’s cancer patients. Our goals are to: 1) give each patient the best possible outcome by individualizing their treatment based on their tumor’s genomic subtype; 2) learn as much as possible from each patient’s response, and 3) rapidly disseminate what is learned in time to help the next patient. More information is available at www.cancercommons.org.

See Original Press Release

March 9, 2011

Marty Tenenbaum Discusses the Targeted Therapy Finder on CNN

In the News

Marty Tenenbaum, CollabRx CEO, discusses the CollabRx Targeted Therapy Finders on CNN’s Anderson Cooper 360.

January 17, 2011

Marty Tenenbaum Talks to Chris Jansing on Cancer Treatment

In the News

Marty Tenenbaum, CollabRx CEO, is interviewed on MSNBC by Chris Jansing.

August 31, 2010

Google buys Angstro and hires founder to help build social networking service

In the News

Highly respected entrepreneur and Internet researcher Rohit Khare has sold his company Angstro to Google and taken a job at the Internet giant to help build its social networking product Google Me.


Angstro was a CommerceNet portfolio company.


March 30, 2010

Dr. Jay M. Tenenbaum Awarded AAAI Robert S. Engelmore Memorial Lecture Award

In the News

Dr. Jay M. Tenenbaum has been selected as the eighth recipient of the AAAI Robert S. Engelmore Memorial Lecture Award, sponsored by IAAI and AI Magazine. This award was established in 2003 to honor Bob’s extraordinary service to AAAI, AI Magazine, and the AI applications community, as well as his contributions to applied AI. The award is given to people who have shown extraordinary service to AAAI and the AI community. The award will be presented at IAAI-10 in Atlanta.

Learn more and register


March 18, 2010

PatientsLikeMe Collaborates With Novartis To Create An Open Online Community For Organ Transplant Recipients. Two New Programs Unveiled to Help Patients “Give Back”

In the News

PatientsLikeMe announces the launch of a free online community for people who have received organ transplants, including heart, lung, liver and kidney. Global healthcare leader Novartis is supporting the development of this community.

Patients Like Me is a CommerceNet portfolio company.

Read full article.